6/28/23, 11:44 PM OCEAN(a)-DOSE (olpasiran 10 mg) Pathway Feedback Search Clinical Topics Home Studies OCEAN(a)-DOSE (olpasiran 10 mg) OCEAN(a)-DOSE (olpasiran 10 mg) Disease Disease Disease Acute ischemic stroke Coronary artery disease Dyslipidem Trial question What is the role of olpasiran in patients with established ASCVD? Study design Multi-center Double blinded RCT Population Characteristics of study participants 27.0% female N = 112 73.0% male 112 patients (30 female, 82 male) Inclusion criteria: patients with established ASCVD and a lipoprotein(a) concentration > 150 nmol/L Key exclusion criteria: severe renal dysfunction or active liver disease Interventions N=58 olpasiran (at a dose of 10 mg every 12 week) N=54 placebo (matching placebo every 12 week) Primary outcome https://web.pathway.md/studies/reclihdmsvlRV9Z4c 1/2 6/28/23, 11:44 PM OCEAN(a)-DOSE (olpasiran 10 mg) Pathway Significant increase in percent reduction in lipoprotein A concentration at week 36 (66.9% vs. -3.6%; AD 70.5%, 95% CI 65.9 to 75.1) Secondary outcomes Significant increase in percent reduction in low-density lipoprotein cholesterol concentration at week 36 (17.4% vs. -6.3%; AD 23.7%, 95% CI 12.2 to 35.3) Significant increase in percent reduction in ApoB concentration at week 36 (11.5% vs. -7.4%; AD 18.9%, 95% CI 11.5 to 26.3) Safety outcomes No significant difference in adverse and serious adverse events. Conclusion In patients with established ASCVD and a lipoprotein(a) concentration > 150 nmol/L, olpasiran was superior to placebo with respect to percent reduction in lipoprotein A concentration at week 36. Reference Michelle L O'Donoghue, Robert S Rosenson, Baris Gencer et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022 Nov 17;387(20):1855-1864. Open reference URL https://web.pathway.md/studies/reclihdmsvlRV9Z4c 2/2